Rifaximin is a low solubility antibiotic with activity against a wide range of bacterial 28 pathogens. It accumulates in the intestine and is suitable for prolonged use. Three chemostat 29 models (A, B and C) were used to investigate the effects of three rifaximin formulations (α, β 30 and κ, respectively) on the gut microbiome. Bacterial populations were monitored by 31 bacterial culture and 16S rRNA gene amplicon (16S) sequencing. Limited disruption of 32 bacterial populations was observed for rifaximin α, β and κ. All formulations caused declines 33 in total spores (~2 log10 cfu ml -1 ), Enterococcus spp. (~2 log10 cfu ml -1 in models A and C, 34 and ~1 log10 cfu ml -1 in model B), and Bacteroides spp. populations (~3 log10 cfu ml -1 in 35 models A and C, and ~4 log10 cfu ml -1 in model B). Bacterial populations fully recovered 36 during antibiotic dosing in model C, and before the end of the experiment in models A and B.
Introduction 47
Materials and Methods 85 86 In vitro gut model and experimental design 87 Three triple-stage chemostat models were assembled as previously described [18, 24] , and 88 run in parallel. Briefly, each model consisted of three glass vessels maintained at 37°C and 89 arranged in a weir cascade. Each vessel represents the conditions of the human colon, from 90 proximal to distal, in pH and nutrient availability. The models were continuously fed with 91 complex growth media [18] connected to vessel 1 at a pre-established rate of 0.015h -1 and an 92 anaerobic environment was maintained by sparging the system with nitrogen. Sample ports in 93 all vessels allowed sample collection for monitoring of microbiota populations and antibiotic 94 instillation. All models were initiated with a slurry of pooled human faeces from healthy 95 volunteers (n=4) with no history of antibiotic therapy in the previous 6 months, diluted in 96 pre-reduced phosphate-buffered saline (PBS) (10% w/v). Bacterial populations were allowed 97 to equilibrate for 2 weeks (equilibration period) prior to antibiotic exposure (rifaximin dosing 98 period), and to recover for 3 weeks post antibiotic dosing (recovery period), as outlined in 99 Fig. 1 . Three proprietary rifaximin formulations, named in this study as alpha-α, beta-β, and 100 kappa-κ (supplied by Teva Pharmaceuticals USA, Parsippany, NJ, USA) were investigated. 101 Model A was inoculated with rifaximin α, model B was inoculated with rifaximin β and 102 model C was inoculated with rifaximin κ. Only one model was used per formulation, as the 103 reproducibility and clinically reflective nature of this system has been shown [16, 21, [23] [24] [25] . 104 Due to rifaximin poor solubility, each antibiotic dose was suspended in water and added to 105 vessel 1 of the respective model. Each model was dosed with 400 mg of rifaximin, thrice 106 daily, for 10 days, to replicate the dosing regimen previously used in human clinical trials [4], 107 and the rifaximin concentration that reaches the human colon. No adjustments to the dosing 108 concentration were performed based on the gut model vessel volumes, since the oral 109 6 administration of a single radiolabelled dose of 400 mg of rifaximin to healthy individuals 110 showed that nearly all rifaximin (~97%) is excreted in the faeces [2] . Selective and non-111 selective agars (Table 1) were used for culture profiling of total facultative and obligate 112 anaerobes, Enterobacteriaceae, Enterococcus spp., Bifidobacterium spp., Bacteroides spp.,
113
Lactobacillus spp., Clostridium spp., and total spores, as previously described [18] , supported 114 by MALDI-TOF for specific colony/species identification. Bacterial populations in vessel 3 115 were monitored by inoculating the agar plates in triplicate every other day prior to antibiotic 116 exposure and daily thereafter. The limit of detection for culture assay was established at 117 ~1.22 log10 cfu ml -1 . Additional samples were taken from vessel 3 of each model to 118 investigate bacterial diversity by 16S sequencing as outlined in Fig. 1 . Vessel 3 was 119 particularly investigated due to its microbial richness and representation of the human colon 120 region more physiologically relevant for opportunistic infections [16, 18, 24] . Sequencing analysis was performed as previously described [27] . Briefly, de-multiplexed 144 FASTQ files were trimmed of adapter sequences using cutadapt [28] . Paired reads were 145 merged using fastq-join [29] under default settings and then converted to FASTA format.
146
Consensus sequences were removed when containing ambiguous base calls, two contiguous 147 bases with a PHRED quality score lower than 33 or a length more than 2 bp different from 148 the expected length of 240 bp. Further analysis was performed using QIIME [30] . Clostridium spp. (~1 log10 cfu ml -1 ) populations ( Fig. 2a and Fig. S1a ). Total spores,
197
Bifidobacterium spp. and Bacteroides spp. populations recovered during antibiotic instillation 198 period. Enterococcus spp. recovered to pre-antibiotic levels by the end of the experiment..
199
Following rifaximin α instillation, Clostridium spp. populations remained at ~6 log10 cfu ml -1 200 throughout the experiment (Fig. S1a ).
201
In model B, effects of exposure to rifaximin β were similar to those of rifaximin α ( Fig. 2b   202 and Fig. S1b ). Declines were observed in Enterococcus spp. (~1 log10 cfu ml -1 ), total spores 203 (~2 log10 cfu ml -1 ), Bacteroides spp. populations (~4 log10 cfu ml -1 ), and Clostridium spp. (~1 204 log10 cfu ml -1 ). Enterococcus spp. populations recovered 4 days post antibiotic dosing and 205 showed a further ~1 log10 cfu ml -1 increase 11 days post cessation of antibiotic instillation. cfu ml -1 ) populations ( Fig. 2c and Fig. S1c ). All populations recovered before the end of 214 antibiotic dosing, but Bifidobacterium spp. showed a further decline of ~1 log10 cfu ml -1 215 approximately a week after antibiotic exposure ended. Following recovery, Enterococcus 216 spp. and Bacteroides spp. populations remained ~1 log10 cfu ml -1 higher compared with pre 217 rifaximin κ instillation.
218
In all models, populations of total obligate anaerobes, total facultative anaerobes and lactose-219 fermenting Enterobacteriaceae remained stable throughout the experiment (Fig. S1 ). Whilst 220 the levels of the total spores initially recovered to pre-antibiotic levels, in all models they 221 later declined by ~1 log10 cfu ml -1 , which could be due to germination of these spores. in all models ( Fig. 3 and Table S2 ). In all models, genus Oscillospira and Bifidobacterium 236 were highly abundant throughout the study. During rifaximin exposure, Acidaminococcus 237 abundance increased in models A and B (20% and 11%, respectively). Instillation of 238 rifaximin α and β also increased the relative abundance of Lachnospira in 1.7% and 3.3%, 239 respectively, with this genus remaining highly prevalent up to the end of the experiment in 240 both models. The relative abundance of genera Oscillospira declined (5.8% and 26.5%, with 241 antibiotic dosing in models A and B, respectively. In models A and B, relative abundance of 242 genus Bacteroides decreased at the start of antibiotic dosing but recovered still during 243 antibiotic instillation (from 0.39% to 0.7% in model A; and from 0.16% to 1.19% in model 244 B). These trends are consistent with those observed by direct enumeration ( Fig. 2A and 2B ).
245
Differences between the effects of rifaximin α and β effects were also observed. During 246 antibiotic dosing, genera Megasphaera and Bifidobacterium declined 8.5% and 5.3%, 247 respectively, in model A but increased 3% and 10.7%, respectively, in model B. Relative 248 abundance of genus Faecalibacterium increased 1.8% during rifaximin α instillation, and 249 declined at the same level in presence of rifaximin β (Fig. 3 and Table S2 ).
250
In model C, genera Bifidobacterium, Oscillospira, and Acidaminococcus remained the most 251 prevalent throughout the study. During rifaximin κ exposure, relative abundances of genera 252 Oscillospira, Megasphaera, and Sutterella, increased 5.8%, 1.4% and 1.4%, respectively; 253 whereas relative abundance of Bifidobacterium and Acidaminococcus declined 0.7% and 254 3.5%, respectively. In model C, sequencing data also showed a decline in genus Bacteroides 255 from 0.22% to 0.015% between day 15 and day 20, with this genus recovering during 256 antibiotic instillation (0.38% at day 23), which is consistent with the data observed by culture 257 (Figure 2c) . At the end of the experiment, models A and B showed similar relative abundance 258 of Bifidobacterium (27% in A, 28.2% in B), whereas model C showed a slightly lower 259 abundance of 20.62%. This is also consistent with the observations of bacterial culture, where 260 at the end of the experiment, Bifidobacterium spp. counts are ~1 log10 cfu ml -1 lower in model 261 C, compared to models A and B (Fig. 3 and Table S2 ).
263

Antimicrobial concentrations in Model A, B and C 264
Mean bioactive concentrations of the soluble fraction of rifaximin α, β and κ peaked at 43.1 265 mg l -1 , 36.8 mg l -1 and 61.9 mg l -1 in vessel 3 of models A, B and C, respectively (Fig. 4a ).
266
Overall, the soluble phase of rifaximin was detected in vessel 3 from day 15 and persisted 267 above the limit of detection (8 mg l -1 ) for the remainder of the experiment in all models. We (Fig. 4b) . Antibiotic concentrations in vessel 3 remained above the limit of microbiota populations in the chemostat models than observed with other antibiotics, [19] [20] [21] 282 24] which agrees with previous rifaximin studies [2, 11, 12, 15, 35] . Rifaximin formulations 283 α, β and κ caused similar alterations in the gut microbiota, with some obligate (Bacteroides 284 spp. and Bifidobacterium spp.) and facultative anaerobic (Enterococcus spp.) populations 285 affected the most. Despite rifaximin low solubility, [2, 4] the soluble phase remained above 8 286 mg l -1 in all models throughout the experiment. The insoluble phase showed concentrations 287 100-fold higher than the soluble phase and similar to previously reported rifaximin' faecal 288 concentrations (8000 mg l -1 ) [17] . Biofilm formation in the gut model vessels was previously 289 reported and hypothesised to have a role in fidaxomicin persistence in the gut model [21] .
290
The occasional spikes in antibiotic concentration observed during recovery period could be 291 associated with biofilm detachment from the vessel walls and subsequent release of antibiotic 292 residue retained within the matrix. In all models, culture data showed a decrease of 293 Bacteroides spp. populations at the start of rifaximin instillation, followed by a recovery to 294 equilibration phase levels by the end of antibiotic dosing, and indeed before the elimination 295 of bioactive antibiotic (which persisted in the insoluble phase for at least 3 weeks after dosing 296 ended - Fig. 4 ). This is similar to the variations of the Bacteroides genus shown by the 16S 297 sequencing data, particularly for models A and B. In the literature, Bacteroides abundance 298 has been reported as unchanged [15] or increased [10, 12] after rifaximin dosing, however no 299 testing was performed in those studies during antibiotic dosing. We observed that genus MALDI-TOF identification, and whose polysaccharides are required for a normal immune 306 system response and as such, may play a role in infection prevention [37] . Both bacterial 307 culture and 16S sequencing data showed Bifidobacterium as highly prevalent in all models, 308 with rifaximin exposure causing a decline in models A and C, and an increase in model B.
309
Susceptibility of Bifidobacterium populations to each rifaximin formulation could explain 310 these differences, as Bifidobacterium genus has been shown to be highly resistant to 311 rifaximin, with MICs increasing up to 25 mg l -1 during antibiotic exposure [35, 36] . As 312 observed in patient studies, [13, 15, 35] our culture and sequencing data showed recovery of 313 the microbial populations affected by rifaximin instillation, although differences in the 314 relative abundance of some bacterial groups were observed.
315
Overall, taxonomic analysis showed a variety of bacterial families and genera that otherwise 
